Aurigene Pharmaceutical Services provides a flexible and wide range of services and capabilities at each phase of drug lifecycle.
- End-to-end services across the drug lifecycle.
- Integrated services and resources enabling seamless and accelerated development from discovery to commercialization.
- Capabilities to supply from gram scale to multi-ton scale of active ingredients and complex intermediates.
- Core areas of competence in specialized chemistry (peptides, carbohydrates, steroids, mPEGs).
- Standalone and integrated discovery services.
- World-class infrastructure: State-of-the-art R and D and manufacturing facilities audited by major international regulatory agencies.
- Biotherapeutic modalities including proteins, antibodies, ADCs, CAR Ts, mRNAs.
- Drug product capabilities from formulation development to commercial production in GMP facilities.
-
Hit Generation
-
Lead
Identification -
Lead
Optimization
- Early stage drug discovery accelerating innovations for small and large molecules.
- FTE/FFS services in medicinal chemistry, computational chemistry, discovery biology. and large molecule modalities.
-
Development
Phase 1 -
Development:
Phase 2 -
Development:
Phase 3
- Helping our partners to bring their innovations to the market faster through phase appropriate development services.
- Process development and non-GMP supplies and technology transfer.
- GMP clinical supplies for API and drug product.
Commercial
Manufacturing
- Ensuring a sustainable supply of APIs and finished formulations.
- Continuous improvement and reliable commercial supplies from 8 US FDA inspected facilities.
Range of our services
Aurigene Pharmaceutical Services offers end-to-end capabilities across drug discovery, development and manufacturing of APIs and formulations. We have discovery, development and manufacturing operations in multiple technology platforms including carbohydrates, steroids, PEG derivatives, oligonucleotides, steroids, high-potent APIs and peptides. In addition, we run discovery scale and CDMO scale operations in biotherapeutics services such as ADCs, mAbs, mRNAs and CAR Ts.
Aurigene Pharmaceutical Services CRO/CDMO
Small
Molecules
Large Molecules
Biotherapeutics
Formulation
Services
Why Aurigene Pharmaceutical Services?
Our focus on scientific expertise and integrated services along with our strong fundamentals on quality infrastructure, sustainability operations, and information security makes us a preferred partner.
Truly integrated services
We offer one-stop solutions for
- Integrated Discovery chemistry and Biology services
- Small molecule and Large molecule services
- Services from early discovery to commercialization
- Global regulatory and quality expertise
- Pre-formulation and formulation service
- Analytical and purification expertise
Quality
- Our R and D site is US FDA inspected cGMP sites have multiple accreditations across globe, All our labs are GLP approved, animal facilities are AAALAC accredited
Science
- Strong technology platforms Niche/Sensitive/Complex chemistry expertise
Infrastructure
- 2 R and D centers, 8 US FDA inspected cGMP sites, AAALAC accredited vivarium
Information Security
- 360-degree information security coverage with adequate back-up plan, business continuity plan and information security interventions
Business Continuity
- Structured assurance and governance measures
People
- We strive to hire the best talent and train them,
700+ scientists, >95% of scientists are post-graduates or above
ESG
- Commitment to highest standards of Environment, Social and Governance; Dow Jones, CDP, PSCI, approved
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Methoxy Polyethylene Glycol (m-PEGs)
Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...
Read More
Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones
2020
A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...
Read More-
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation
2005
An improved and rapid synthesis of mefenamic acid based indole derivatives has been achieved via the ligand free Cu-catalyzed coupling-cyclization method under ultrasound irradiation. This simple, straightforward and inexpensive one-pot method involved the reaction of a terminal alkyne derived from mefenamic acid with 2- iodosulfanilides in the presence of CuI ...
Read More -
Formal synthesis of Cladospolide C & epi-Cladospolide C using R- (þ)-g-valerolactone as a chiral synthon
2005
The formal synthesis of Cladospolide-C and its analog is achieved by using enantiopure (R)-g evalerolactone 10. The significant points of this synthesis are the stereoselective dihydroxylation of a, bunsaturated ester 16 using Sharpless protocol, Wittig olefination of g evalerolactol 6 with triphenylphosphonium iodide salt 7, one pot selective oxidation ...
Read More -
Amberlite-15 promoted an unprecedented aza Michael rearrangement for one pot synthesis of dihydroquinazolinone compounds
2005
A new one pot multicomponent annulation strategy for the synthesis of various dihydroquinazolinone compounds has been developed using Amberlite-15 as a catalyst, giving good to moderate yields. In this reaction the substrate scope for amines and aldehydes was also investigated. The reaction has been checked on a large scale ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market